MyoKardia Inc(MYOK)stock report

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Finance:
Q3 2019(9/30/19): Cash 417M. Loss 141.36M

EPS and Sales:
https://finance.yahoo.com/quote/MYOK/financials?p=MYOK

Date EPS % last year % last quarter
2018.12.31 -1.76 -1.15% -27.54%
2019.3.31 -0.93 -86.00% 47.16%
2019.6.30 -1.75 -76.77% 11.00%
2019.9.30 -4.91 -255.80% -180.57%

 

2019Sales:0

Insider Transactions:
http://insidercow.com/history/company.jsp?company=MYOK&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/MYOK/institutional-ownership/

2019.12.23:
Total institutions: 183,no change
Shares hold: 50094.5k shares. no change
shares% hold: 108.37%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/MYOK/price-targe

Leave a Reply